Table 3 10-year average cost, number of exacerbations, and quality adjusted life-years for each intervention using both pairwise meta-analysis (PMA) and network meta-analysis (NMA)
Intervention | Meta-analysis | Costs ($) | Number of exacerbations | Quality adjusted life years (QALYs) |
|---|---|---|---|---|
Placebo | PMA | 25 458 (19 927, 32 312) | 12.6 (12.5, 12.8) | 5.67 (5.36, 5.99) |
NMA | 25 316 (19 950, 31 897) | 12.6 (12.5, 12.7) | 5.67 (5.34, 5.99) | |
ICS | PMA | 27 116 (22 194, 33 307) | 10.3 (8.62, 11.9) | 5.73 (5.40, 6.07) |
NMA | 26 979 (21 991, 33 420) | 10.2 (9.10, 11.4) | 5.73 (5.38, 6.06) | |
LABA | PMA | 28 304 (23 081, 34 897) | 11.0 (9.31, 13.2) | 5.71 (5.39, 6.04) |
NMA | 28 116 (23 002, 34 604) | 10.9 (9.86, 12.2) | 5.71 (5.37, 6.05) | |
ICS + LABA | PMA | 30 849 (25 947, 36 741) | 9.13 (7.69, 11.2) | 5.76 (5.42, 6.10) |
NMA | 30 496 (25 902, 36 133) | 8.85 (7.83, 10.0) | 5.75 (5.40, 6.11) | |
LAMA | PMA | 28 840 (23 928, 35 073) | 9.33 (7.47, 11.4) | 5.76 (5.42, 6.10) |
NMA | 28 816 (24 237, 34 548) | 9.39 (8.37, 10.4) | 5.77 (5.41, 6.12) |